RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Staidson Beijing BioPharmaceuticals Co - Stock

Staidson Beijing BioPharmaceuticals Co Liabilities 2024

Staidson Beijing BioPharmaceuticals Co Liabilities

311.55 M CNY

Staidson Beijing BioPharmaceuticals Co Dividend yield

11.13 %

Ticker

300204.SZ

ISIN

CNE100001237

In 2024, Staidson Beijing BioPharmaceuticals Co's total liabilities amounted to 311.55 M CNY, a -1.24% difference from the 315.45 M CNY total liabilities in the previous year.

Staidson Beijing BioPharmaceuticals Co Aktienanalyse

What does Staidson Beijing BioPharmaceuticals Co do?

Staidson Beijing BioPharmaceuticals Co Ltd is a leading biopharmaceutical company based in Beijing, China. The company has a long history and a wide range of products and services that make it an important player in the biotechnology field. Staidson Beijing BioPharmaceuticals Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Staidson Beijing BioPharmaceuticals Co's Liabilities

Staidson Beijing BioPharmaceuticals Co's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Staidson Beijing BioPharmaceuticals Co's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Staidson Beijing BioPharmaceuticals Co's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Staidson Beijing BioPharmaceuticals Co's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Staidson Beijing BioPharmaceuticals Co’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Staidson Beijing BioPharmaceuticals Co Stock

What is the level of liabilities of Staidson Beijing BioPharmaceuticals Co this year?

Staidson Beijing BioPharmaceuticals Co has a debt balance of 311.55 M CNY this year.

What were the liabilities of Staidson Beijing BioPharmaceuticals Co compared to the previous year?

The liabilities of Staidson Beijing BioPharmaceuticals Co have increased by -1.24% dropped compared to the previous year.

What are the consequences of high debt for investors of Staidson Beijing BioPharmaceuticals Co?

High liabilities can pose a risk for investors of Staidson Beijing BioPharmaceuticals Co, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Staidson Beijing BioPharmaceuticals Co?

Low liabilities mean that Staidson Beijing BioPharmaceuticals Co has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Staidson Beijing BioPharmaceuticals Co affect the company?

An increase in liabilities of Staidson Beijing BioPharmaceuticals Co can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Staidson Beijing BioPharmaceuticals Co affect the company?

A decrease in the liabilities of Staidson Beijing BioPharmaceuticals Co can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Staidson Beijing BioPharmaceuticals Co?

Some factors that can influence the liabilities of Staidson Beijing BioPharmaceuticals Co include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Staidson Beijing BioPharmaceuticals Co so important for investors?

The liabilities of Staidson Beijing BioPharmaceuticals Co are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Staidson Beijing BioPharmaceuticals Co take to modify the liabilities?

To change its liabilities, Staidson Beijing BioPharmaceuticals Co can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Staidson Beijing BioPharmaceuticals Co pay?

Over the past 12 months, Staidson Beijing BioPharmaceuticals Co paid a dividend of 0.67 CNY . This corresponds to a dividend yield of about 11.13 %. For the coming 12 months, Staidson Beijing BioPharmaceuticals Co is expected to pay a dividend of 0 CNY.

What is the dividend yield of Staidson Beijing BioPharmaceuticals Co?

The current dividend yield of Staidson Beijing BioPharmaceuticals Co is 11.13 %.

When does Staidson Beijing BioPharmaceuticals Co pay dividends?

Staidson Beijing BioPharmaceuticals Co pays a quarterly dividend. This is distributed in the months of June, May, April, June.

How secure is the dividend of Staidson Beijing BioPharmaceuticals Co?

Staidson Beijing BioPharmaceuticals Co paid dividends every year for the past 0 years.

What is the dividend of Staidson Beijing BioPharmaceuticals Co?

For the upcoming 12 months, dividends amounting to 0 CNY are expected. This corresponds to a dividend yield of 0 %.

In which sector is Staidson Beijing BioPharmaceuticals Co located?

Staidson Beijing BioPharmaceuticals Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Staidson Beijing BioPharmaceuticals Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Staidson Beijing BioPharmaceuticals Co from 5/17/2019 amounting to 0.668 CNY, you needed to have the stock in your portfolio before the ex-date on 5/17/2019.

When did Staidson Beijing BioPharmaceuticals Co pay the last dividend?

The last dividend was paid out on 5/17/2019.

What was the dividend of Staidson Beijing BioPharmaceuticals Co in the year 2023?

In the year 2023, Staidson Beijing BioPharmaceuticals Co distributed 0 CNY as dividends.

In which currency does Staidson Beijing BioPharmaceuticals Co pay out the dividend?

The dividends of Staidson Beijing BioPharmaceuticals Co are distributed in CNY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Staidson Beijing BioPharmaceuticals Co

Our stock analysis for Staidson Beijing BioPharmaceuticals Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Staidson Beijing BioPharmaceuticals Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.